LivaNova (NASDAQ:LIVN) Price Target Raised to $112.00

LivaNova (NASDAQ:LIVN) had its price target hoisted by Needham & Company LLC from $93.00 to $112.00 in a report released on Wednesday,Benzinga reports. Needham & Company LLC currently has a buy rating on the stock.

Other analysts have also recently issued research reports about the stock. Weiss Ratings upgraded shares of LivaNova from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, October 27th. Stifel Nicolaus set a $85.00 price target on LivaNova in a report on Wednesday, August 5th. Mizuho boosted their target price on shares of LivaNova from $90.00 to $95.00 and gave the company an “outperform” rating in a research note on Wednesday, July 15th. Piper Sandler reiterated an “overweight” rating and issued a $90.00 price objective (up from $87.00) on shares of LivaNova in a research note on Wednesday, September 2nd. Finally, Barclays upgraded LivaNova to a “strong-buy” rating in a research report on Wednesday, October 7th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $99.56.

LivaNova Price Performance

Shares of NASDAQ:LIVN traded down $1.15 on Wednesday, hitting $89.99. The company’s stock had a trading volume of 443,974 shares, compared to its average volume of 553,701. LivaNova has a 1 year low of $49.73 and a 1 year high of $99.38. The company has a market capitalization of $4.96 billion, a PE ratio of 30.00 and a beta of 0.91. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.45 and a quick ratio of 1.21. The company has a 50-day simple moving average of $79.27 and a 200 day simple moving average of $73.54.

LivaNova (NASDAQ:LIVN) last posted its quarterly earnings results on Wednesday, November 4th. The company reported $1.23 EPS for the quarter, topping the consensus estimate of $1.06 by $0.17. The firm had revenue of $393.15 million for the quarter, compared to the consensus estimate of $381.13 million. LivaNova had a net margin of 12.82% and a return on equity of 16.35%. The business’s revenue was up 9.9% compared to the same quarter last year. During the same period last year, the firm posted $1.11 earnings per share. Sell-side analysts forecast that LivaNova will post 3.79 EPS for the current fiscal year.

Insider Activity

In other LivaNova news, Director Brooke Story sold 2,300 shares of LivaNova stock in a transaction on Friday, September 4th. The shares were sold at an average price of $81.42, for a total value of $187,266.00. Following the transaction, the director directly owned 7,488 shares of the company’s stock, valued at approximately $609,672.96. The trade was a 23.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Francesco Bianchi sold 3,500 shares of the business’s stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $78.01, for a total value of $273,035.00. Following the transaction, the director owned 4,434 shares in the company, valued at approximately $345,896.34. This trade represents a 44.11% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 7,450 shares of company stock valued at $591,839. Company insiders own 0.35% of the company’s stock.

Institutional Investors Weigh In On LivaNova

A number of hedge funds and other institutional investors have recently made changes to their positions in LIVN. Allworth Financial LP increased its stake in shares of LivaNova by 93.5% during the second quarter. Allworth Financial LP now owns 298 shares of the company’s stock worth $25,000 after purchasing an additional 144 shares in the last quarter. Farther Finance Advisors LLC boosted its stake in LivaNova by 59.7% during the third quarter. Farther Finance Advisors LLC now owns 452 shares of the company’s stock worth $35,000 after buying an additional 169 shares during the last quarter. State of Michigan Retirement System increased its stake in shares of LivaNova by 1.5% in the 1st quarter. State of Michigan Retirement System now owns 13,111 shares of the company’s stock worth $833,000 after acquiring an additional 200 shares during the last quarter. Hohimer Wealth Management LLC raised its stake in LivaNova by 5.4% during the third quarter. Hohimer Wealth Management LLC now owns 4,277 shares of the company’s stock worth $327,000 after purchasing an additional 219 shares during the period. Finally, GAMMA Investing LLC raised its position in shares of LivaNova by 12.5% during the 3rd quarter. GAMMA Investing LLC now owns 2,068 shares of the company’s stock valued at $158,000 after buying an additional 230 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova PLC (NASDAQ: LIVN) is a medical technology company that develops and manufactures devices and therapies for patients with neurological and cardiovascular conditions. Its products are used by hospitals, physicians and other healthcare providers in markets around the world.

The company’s Neuromodulation business is best known for VNS Therapy, which uses an implanted device to deliver electrical stimulation to the vagus nerve. The therapy is used primarily for drug-resistant epilepsy and treatment-resistant depression, subject to applicable regulatory approvals.